PF-06410293: An Adalimumab Biosimilar.

Adalimumab / adverse effects Arthritis, Rheumatoid / drug therapy Biosimilar Pharmaceuticals / adverse effects Humans Tumor Necrosis Factor-alpha

Journal

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305

Informations de publication

Date de publication:
Oct 2020
Historique:
pubmed: 20 9 2020
medline: 28 4 2021
entrez: 19 9 2020
Statut: ppublish

Résumé

PF-06410293 (Amsparity

Identifiants

DOI: 10.1007/s40259-020-00445-8 PMID: 32949384
pubmed: 32949384
doi: 10.1007/s40259-020-00445-8
pii: 10.1007/s40259-020-00445-8
doi:

Substances chimiques

Biosimilar Pharmaceuticals 0
PF-06410293 0
Tumor Necrosis Factor-alpha 0
Adalimumab FYS6T7F842

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

695-698

Auteurs

Arnold Lee (A)

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
ORCID: 0000-0002-6519-7831

Matt Shirley (M)

Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Anticorps monoclonaux humanisés › Adalimumab › PF-06410293: An Adalimumab Biosimilar.
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Polyarthrite rhumatoïde › PF-06410293: An Adalimumab Biosimilar.
questionsmedicales.fr › Mélanges complexes › Produits biologiques › Produits pharmaceutiques biosimilaires › PF-06410293: An Adalimumab Biosimilar.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › PF-06410293: An Adalimumab Biosimilar.
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Cytokines › Facteurs de nécrose tumorale › Facteur de nécrose tumorale alpha › PF-06410293: An Adalimumab Biosimilar.